MRK vs MRNA
By Alex · Tickerpine
Merck & Co., Inc. vs Moderna, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | MRNA |
|---|---|---|
| Price | $156.45 | $158.83 |
| Market cap | $385.99B | $63.41B |
| P/E ratio | 120.3 | — |
| ROE | 6.96% | -39.00% |
| Profit margin | 4.77% | -141.43% |
| Revenue growth | 5.10% | 2.10% |
| Dividend yield | 2.26% | — |
| Beta | 0.21 | 0.90 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs MRNA in plain English
- MRK is the bigger company — about 6.1× the market cap of MRNA.
- MRK earns a higher return on equity (7% vs -39%).
- MRK is growing revenue faster (5% vs 2%).
- MRK pays a dividend (2.26%) while the other effectively doesn't.
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
MRNA return calculator
See what $1,000 in Moderna, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.